Enovis (NYSE:ENOV) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Enovis (NYSE:ENOV) announced its quarterly earnings data on Thursday. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05, FiscalAI reports. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm had revenue of $582.78 million for the quarter, compared to the consensus estimate of $581.84 million. During the same period in the prior year, the company posted $0.79 earnings per share. The business’s revenue for the quarter was up 3.2% on a year-over-year basis. Enovis updated its FY 2026 guidance to 3.520-3.730 EPS.

Here are the key takeaways from Enovis’ conference call:

• Second-quarter organic sales grew 5%, led by 6% growth in Recon and 3% in PNR. U.S. Recon hips and knees and extremities each grew 8% in the first half, while Nebula, ARG, and the full commercial launch of ARVIS are gaining traction.
• Adjusted gross margin improved 120 basis points on an underlying basis, and adjusted EBITDA margin rose 70 basis points to 17.9%. Management cited favorable product mix, productivity, and Lima integration synergies, and expects continued multi-year margin expansion.
• Free cash flow improved by $27 million year over year to $31 million in the quarter, bringing first-half cash flow slightly positive. The company reaffirmed its target of greater than 25% free-cash-flow conversion for 2026 and aims to reduce leverage below 3x.
• Enovis reaffirmed its 2026 guidance but expects a seasonally weaker-than-usual third quarter because of softer Western European markets and Middle East-related disruption, followed by sales acceleration in the fourth quarter.
• Inflationary pressure from raw materials, freight, distribution, and the Middle East conflict reduced second-quarter results by $2 million and is expected to total a $10 million full-year impact. Management said passing through additional costs remains difficult, particularly in PNR, because of competitive and market pressures.

Enovis Price Performance

Shares of ENOV stock traded up $0.38 on Friday, reaching $26.68. The company had a trading volume of 2,058,436 shares, compared to its average volume of 1,111,529. The stock has a market capitalization of $1.54 billion, a PE ratio of -1.39 and a beta of 1.34. The company has a quick ratio of 1.05, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. Enovis has a one year low of $19.14 and a one year high of $34.28. The business’s 50-day moving average is $24.62 and its 200 day moving average is $23.97.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ENOV. Wells Fargo & Company cut their price target on shares of Enovis from $40.00 to $39.00 and set an “overweight” rating for the company in a report on Friday. BMO Capital Markets reissued an “outperform” rating and issued a $30.00 price objective on shares of Enovis in a research note on Friday. Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. UBS Group restated a “buy” rating and set a $51.00 target price (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. Finally, BTIG Research raised their target price on Enovis from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Enovis News Roundup

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported second-quarter adjusted earnings of $0.90 per share, above the $0.85 analyst consensus and up from $0.79 a year earlier. Revenue of $582.8 million was also slightly ahead of estimates, while sales increased 3.2% year over year. Enovis Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management reaffirmed its full-year 2026 outlook, including revenue of approximately $2.3 billion to $2.4 billion and adjusted EPS guidance of $3.52 to $3.73. Reconstructive sales were a relative bright spot, rising 8% on a reported basis and 6% organically. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: BTIG Research raised its price target from $39 to $40 and maintained a Buy rating, implying substantial potential upside from recent trading levels. BTIG Research Price Target
• Neutral Sentiment: Wells Fargo lowered its price target modestly from $40 to $39 but retained an Overweight rating, indicating continued long-term confidence despite near-term concerns. Wells Fargo Price Target
• Negative Sentiment: The market reaction was negative because Enovis’ second-quarter performance was characterized as “softer than expected.” Although revenue and EPS exceeded published estimates, investors appear focused on the relatively modest 3% reported sales growth and the lack of an upward guidance revision. Enovis Shares Drop After Second-Quarter Earnings
• Negative Sentiment: Enovis continues to report a deeply negative GAAP net margin, which may reinforce investor concerns about profitability and execution even though adjusted earnings improved. Enovis Q2 2026 Earnings Call Transcript

Insider Buying and Selling at Enovis

In related news, insider Oliver Engert purchased 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average cost of $21.62 per share, with a total value of $25,944.00. Following the acquisition, the insider owned 51,840 shares of the company’s stock, valued at $1,120,780.80. This trade represents a 2.37% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders have purchased 4,200 shares of company stock valued at $92,084. Company insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

A number of hedge funds have recently added to or reduced their stakes in ENOV. Arax Advisory Partners acquired a new position in shares of Enovis during the fourth quarter worth $29,000. EverSource Wealth Advisors LLC lifted its stake in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the last quarter. Danske Bank A S acquired a new stake in shares of Enovis during the 3rd quarter valued at $64,000. iSAM Funds UK Ltd acquired a new stake in shares of Enovis during the 3rd quarter valued at $80,000. Finally, Brown Brothers Harriman & Co. bought a new stake in Enovis during the 3rd quarter worth $90,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.